<DOC>
	<DOCNO>NCT00625625</DOCNO>
	<brief_summary>RATIONALE : Diagnostic procedure , lymph node mapping surgery sentinel lymph node biopsy , may help doctor find micrometastases predict cancer recurrence . PURPOSE : This phase II trial study well lymph node mapping surgery together sentinel lymph node analysis blood test work detect predict early micrometastases patient colorectal cancer .</brief_summary>
	<brief_title>Lymphatic Mapping , Sentinel Lymph Node Analysis , Blood Tests Detecting Predicting Early Micrometastases Patients With Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To determine accuracy sensitivity intraoperative lymph node map isosulfan blue sentinal node biopsy ( SLN ) patient colorectal cancer ( CRC ) . - To compare molecular immunohistochemical method detection micrometastases SLN primary tumor evaluate clinical outcome . - To evaluate clinicopathological utility hematogenous micrometastases predict disease recurrence CRC . OUTLINE : Patients receive isosulfan blue subserosally around primary tumor sentinel lymph node ( SLN ) identification SLN ( ) mark . Patients undergo standard colon resection plan include SLN ( ) regional lymph node . Lymph nod remove surgery analyze within 30 day surgery . Routine pathologic analysis ( H &amp; E ) perform lymph node ( SLN non-SLN ) remove . Immunohistochemical ( IHC ) stain cytokeratin antibody AE-1/AE-3 MAK-6 perform lymph node negative H &amp; E . Multimarker PCR ( MM PCR ) perform SLNs . Blood sample collect baseline periodically 4 year MM PCR detect circulate tumor cell standard tumor marker ( e.g. , CEA ) . After surgery , patient follow every 6 month 4 year .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis colorectal cancer detect proctosigmoidoscopy , flexible endoscopy , gastrografin/barium enema No evidence distant metastasis CT scan abdomen pelvis AND chest xray CT scan chest perform within 6 week prior enrollment Preoperative CT scan test show nonspecific nondiagnostic ( equivocal ) abnormality may eligible pending intraoperative exploration No discovery distant metastases intraoperatively PATIENT CHARACTERISTICS : ECOG performance status ( PS ) Zubrod PS equal 2 Life expectancy &gt; 5 year include disease/diagnosis colorectal cancer Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No requirement emergent surgery ( within 2 hour presentation ) prevent lifethreatening situation death include : Perforated colon Metabolically significant complete bowel obstruction Massive GI bleed Occult bleed early partial bowel obstruction require emergent surgery allow No history Crohn disease , chronic ulcerative colitis , familial polyposis No malignancy within past 3 year except completely resected cervical cancer , skin cancer , situ cancer PRIOR CONCURRENT THERAPY : See Disease Characteristics See Patient Characteristics No concurrent participation another research protocol Participation follow allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2008</verification_date>
	<keyword>stage I colon cancer</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage I rectal cancer</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
</DOC>